지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.12
- 수록면
- 59 - 69 (11page)
이용수
초록· 키워드
오류제보하기
Immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-PD-L1 Abs, have shown efficacy for the treatment of various cancers. Although research has actively sought to develop new ICIs and immunomodulators, no efficient in vitro assay system is available to evaluate their functional activities. In the present study, we established a two-round MLR with human PBMCs for evaluation of the T cell-activating capacity of anti-PD-1 and other immunomodulators. We initially performed conventional MLR for this purpose. However, anti-PD-1 blocking Abs could not increase the proliferation of allo-reactive T cells in conventional MLR because PD-L1<SUP>+</SUP> and PD-L2<SUP>+</SUP> cells disappeared gradually during MLR. Therefore, we re-applied the same stimulator PBMCs to the allo-stimulated responder cells as a second-round MLR on day 6 when anti-PD-1 or immunomodulators were also added. In this two-round MLR, the proliferation of allo-reactive T cells was enhanced by anti-PD-1 in a dose-dependent manner or by immunomodulators, such as lenalidomide and galunisertib, a TGF-β receptor-1 inhibitor. Proliferation was further increased by the combination of immunomodulators with anti-PD-1. Here, we established a modified two-round MLR method with human PBMCs for evaluation of the functional activities of anti-PD-1 and immunomodulators.
목차
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (25)
참고문헌 신청
Junsik Park / 2016 / Immune checkpoint inhibitors for cancer treatment / Archives of Pharmacal Research 39(11):1577~1587
Weber J / 2017 / Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma / N Engl J Med 377:1824~1835
Robert C / 2015 / Nivolumab in previously untreated melanoma without BRAF mutation / N Engl J Med 372:320~330
Borghaei H / 2015 / Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer / N Engl J Med 373:1627~1639
Brahmer J / 2015 / Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer / N Engl J Med 373:123~135
Weber J / 2017 / Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma / N Engl J Med 377:1824~1835
Robert C / 2015 / Nivolumab in previously untreated melanoma without BRAF mutation / N Engl J Med 372:320~330
Borghaei H / 2015 / Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer / N Engl J Med 373:1627~1639
Brahmer J / 2015 / Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer / N Engl J Med 373:123~135
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy
Immune Network
2020 .02
-
Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
Immune Network
2016 .04
-
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Cancer Research and Treatment
2017 .01
-
PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2019 .12
-
Clinical experience with COVID-19 patients
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Advantages of robotic PD over laparoscopic PD
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Journal of Pathology and Translational Medicine
2017 .01
-
Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity
Annals of Laboratory Medicine
2024 .09
-
자가면역성 췌장염의 치료
대한췌담도학회지
2017 .01
-
Dysphagia Requiring Medical Attention in Parkinson’s Disease: A Korean Population-Based Study
Journal of Korean Medical Science
2023 .04
-
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Journal of Pathology and Translational Medicine
2019 .01
-
Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
Investigative and Clinical Urology
2023 .01
-
Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of Mycobacterium avium Complex Pulmonary Disease
Journal of Korean Medical Science
2022 .10
-
Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
Endocrinology and Metabolism
2021 .01
-
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
Journal of Pathology and Translational Medicine
2019 .01
-
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Immune Network
2020 .06
-
Clinical Implication of High Sensitivity C-Reactive Protein for the Development of Dementia in Parkinson’s Disease
Dementia and Neurocognitive Disorders(대한치매학회지)
2015 .01
-
Machine Learning and AI-driven approaches to study molecular mechanisms of anti-PD1 inhibitor response
대한임상종양학회 학술대회지
2021 .06
-
Development of genetically humanized PD-1 mice capable of evaluating preclinical studies of PD-1 immuno-oncology agents
한국실험동물학회 학술발표대회 논문집
2020 .07
-
Changes in Epidemiological Trends and Rehabilitation Usage in Neurological Diseases in Korea: Parkinson's Disease
뇌신경재활
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2019-517-000338066